Basic Information

Gene symbol CSF2 Synonyms CSF, GMCSF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description colony stimulating factor 2


GTO ID GTC4003
Trial ID NCT03514836
Disease Prostate Cancer
Altered gene E1A|CSF2
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment ONCOS-102|CGTG-102
Co-treatment Cyclophosphamide
PhasePhase1|Phase2
Recruitment statusTerminated
TitleA Phase I/II, Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men With Advanced Metastatic Castration-resistant Prostate Cancer.
Year2018
CountryCzechia
Company sponsorSOTIO a.s.
Other ID(s)SP015
Vector information
Vectoradenovirus
ConstructAd5/3-delta24-GMCSF
Vector typeserotype 5 adenovirus
Transgene/Inserted geneGM-CSF, which enhances antitumor immunity by recruiting antigen-presenting cells (APCs) and natural killer (NK) cells, activates and matures APCs at the tumor site, thereby potentiating the ability of ONCOS-102 to induce cellular immunity against the tumor in which it replicates.
Viral genome modificationONCOS-102 has a genetically modified fiber with a serotype 3 knob for enhanced gene delivery to cancer cells. A 24-bp deletion has been made in the Rb binding site of the E1A gene.
Additional featureGM-CSF

Clinical Result

Cohort 1
Administration route intratumoral infusion
Dosage DCVac, every 21-28 days for up to 10 doses
Pts 5
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph